Jefferies Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $63

Benzinga · 12/30/2025 12:46
Jefferies analyst Maury Raycroft maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $114 to $63.